Precigen Inc. (PGEN) Presents Preclinical Data
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Oil hits five-month high as Houthi attacks stoke supply fears
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- Abbott plans to spin off its nutrition unit as a standalone public company
- Alphabet shares drop ahead of earnings next week
- AMD shares fall amid AI chip sector selloff
- Bloom Energy Corp. (BE) Tops Q3 EPS by 25c, Beats on Revenue; Offers FY26 Guidance
- JetBlue shares fall amid American results, fuel cost concerns
Precigen Presents Preclinical Data for the Next Generation Mesothelin UltraCAR-T® with Intrinsic PD-1 Blockade at the AACR Annual Meeting 2023
April 17, 2023 9:01 AM EDTFirst preclinical data presented for the next generation of the UltraCAR-T platform utilizing a mesothelin (MSLN) chimeric antigen receptor (CAR)
MSLN is overexpressed on multiple solid tumors such as mesothelioma, ovarian cancer and pancreatic cancer
Proprietary technology for checkpoint blockade intrinsic to UltraCAR-T cells has the potential for an improved safety profile and reduced cost by eliminating the need for checkpoint inhibitor combinationÂ
Single administration of next generation MSLN UltraCAR-T incorporating intrinsic PD-1 blockade resulted in robust UltraCAR-T cell expansion and durable persistence leading to... More



